Foretinib
Names
Preferred IUPAC name
N1-[3-Fluoro-4-({6-methoxy-7-[3-(morpholin-4-yl)propoxy]quinolin-4-yl}oxy)phenyl]-N′1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
Other names
XL880; EXEL-2880; GSK1363089; GSK089
Identifiers
3D model (JSmol)
ChEBI
ChEMBL
ChemSpider
DrugBank
ECHA InfoCard 100.158.129 Edit this at Wikidata
KEGG
UNII
  • Key: CXQHYVUVSFXTMY-UHFFFAOYSA-N
  • InChI=1S/C34H34F2N4O6/c1-43-30-20-25-27(21-31(30)45-16-2-13-40-14-17-44-18-15-40)37-12-9-28(25)46-29-8-7-24(19-26(29)36)39-33(42)34(10-11-34)32(41)38-23-5-3-22(35)4-6-23/h3-9,12,19-21H,2,10-11,13-18H2,1H3,(H,38,41)(H,39,42)
  • COc1cc2c(ccnc2cc1OCCCN3CCOCC3)Oc4ccc(cc4F)NC(=O)C5(CC5)C(=O)Nc6ccc(cc6)F
Properties
C34H34F2N4O6
Molar mass 632.665 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

Foretinib is an experimental drug candidate for the treatment of cancer.[1] It was discovered by Exelixis and is under development by GlaxoSmithKline.[2] About 10 Phase II clinical trials have been run.[3] As of October 2015 it appears development has been discontinued.[4]

Foretinib is an inhibitor of the kinase enzymes c-Met and vascular endothelial growth factor receptor 2 (VEGFR-2).[5]

See also

References

  1. ^ Hedgethorne, K.; Huang, P.H. (2010). "Foretinib. c-Met and VEGFR-2 inhibitor, Oncolytic". Drugs of the Future. 35 (11): 893–901. doi:10.1358/dof.2010.35.11.1529012.
  2. ^ "XL880 (GSK1363089)". Exelixis, Inc.
  3. ^ "Foretinib". clinicaltrials.gov.
  4. ^ "Foretinib - AdisInsight". adisinsight.springer.com. Retrieved 16 April 2018.
  5. ^ Qian, F; Engst, S; Yamaguchi, K; Yu, P; Won, KA; Mock, L; Lou, T; Tan, J; et al. (2009). "Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases". Cancer Research. 69 (20): 8009–16. doi:10.1158/0008-5472.CAN-08-4889. PMID 19808973.
Categories